NCT00219596已完成3 期
An 8-Week, Randomized, Open-Label, Parallel Group Study Comparing The Efficacy And Safety Of Xalacom With The Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.8 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2005年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 240
- 试验地点
- 8
- 主要终点
- To demonstrate that Xalacom is as effective as uFC latanoprost and timolol at reducing IOP in subjects with open-angel glaucoma or ocular hypertension
研究概览
简要总结
to compare efficacy and safety of Xalacom with the combination of unfixed Latanoprost and Timolol in subjects with open-angel glaucoma or ocular hypertension
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with open-angle glaucoma or ocular hypertension
排除标准
- •closed/barely open anterior chamber angle or a history of acute angel closure glaucoma
- •Ocular surgery within 3 months
结局指标
主要结局
To demonstrate that Xalacom is as effective as uFC latanoprost and timolol at reducing IOP in subjects with open-angel glaucoma or ocular hypertension
次要结局
- To compare the proportion of subjects reaching specified IOP levels at Week 8 To evaluate the ocular and systemic AEs across all clinic visits
研究者
研究点 (8)
Loading locations...
相似试验
已完成
3 期
A Study of Glaucoma or Ocular Hypertension in Patients Within the United StatesGlaucomaOcular HypertensionNCT00800267Pfizer's Upjohn has merged with Mylan to form Viatris Inc.418
已完成
3 期
A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In PatientsGlaucomaOpen-angle GlaucomaOcular HypertensionNCT00856622Pfizer's Upjohn has merged with Mylan to form Viatris Inc.436
已完成
3 期
A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With GlaucomaGlaucoma, Open-AngleOcular HypertensionNCT00159653Pfizer's Upjohn has merged with Mylan to form Viatris Inc.500
已完成
3 期
A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With GlaucomaOpen Angle GlaucomaOcular HypertensionNCT00277498Pfizer's Upjohn has merged with Mylan to form Viatris Inc.528
已完成
3 期
A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon CancerColorectal CancerNCT00069121Hoffmann-La Roche1,886